Welcome to the international HTA database

Showing [23378 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Tenofovir disoproxil fumarate for hepatitis B: horizon scanning technology briefing
2010	NIHR Health Technology Assessment programme	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
2009	National Institute for Health and Care Excellence (NICE)	Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). NICE interventional procedures guidance 299
2000	NIHR Horizon Scanning Centre (NIHR HSC)	Tension free vaginal tape for urinary incontinence - horizon scanning review
2002	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Tension-free vaginal tape (TVT) for urinary incontinence
2008	Haute Autorite de sante (HAS)	Tension-free vaginal tape and women stress incontinence
2004	Medical Advisory Secretariat (MAS)	Tension-free vaginal tape for stress urinary incontinence
2005	HAYES, Inc.	Tension-free vaginal tape procedure for treatment of female stress urinary incontinence
2002	HAYES, Inc.	Tension-free vaginal tape procedure for treatment of female stress urinary incontinence
2022	National Institute for Health and Care Excellence (NICE)	Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations. NICE technology appraisal guidance 789
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Terahertz intraoperative breast cancer probe
2011	Agency for Healthcare Research and Quality (AHRQ)	Terbutaline pump for the prevention of preterm birth
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Teriflunomide for relapsing multiple sclerosis (MS) - first line
2013	NIHR Health Technology Assessment programme	Teriflunomide for treating relapsing forms of multiple sclerosis
2014	National Institute for Health and Care Excellence (NICE)	Teriflunomide for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 303
2004	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Teriparatide
2008	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture
2006	Canadian Agency for Drugs and Technologies in Health (CADTH)	Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis
2001	NIHR Horizon Scanning Centre (NIHR HSC)	Teriparatide for osteoporosis - horizon scanning review
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Teriparatide for the treatment of osteoporosis
2017	The Regional Health Technology Assessment Centre (HTA-centrum)	Term breech presentation - caesarean section versus vaginal delivery
2001	Israel Center for Technology Assessment in Health Care (ICTAHC)	Terror and medicine - the challenge
2003	Israel Center for Technology Assessment in Health Care (ICTAHC)	Terror and Medicine (New book written by over 100 medical experts in Israel in the fields of medicine dealing with the preparations for and treatment of victims of terror attacks)
2022	Malaysian Health Technology Assessment (MaHTAS)	Tertiary care virtual online consultation between doctor and patient
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Tertomotide for locally advanced or metastatic pancreatic cancer
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Tesaglitazar for type 2 diabetes and associated lipid abnormalities - horizon scanning review
2011	HAYES, Inc.	testing
2014	NIHR Health Services and Delivery Research programme	Testing accelerated experience-based co-design: a qualitative study of using a national archive of patient experience narrative interviews to promote rapid patient-centred service improvement
2007	Haute Autorite de sante (HAS)	Testing and detection of a lupus anticoagulant
1993	Health Council of the Netherlands Gezondheidsraad (GR)	Testing and prediction
2006	Agency for Healthcare Research and Quality (AHRQ)	Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure
2012	Medical Services Advisory Committee (MSAC)	Testing for BRAF mutation in patients with metastatic melanoma for access to (1c) vemurafenib
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Testing for clostridium difficile in oncology patients
2007	Agency for Healthcare Research and Quality (AHRQ)	Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
2013	Medical Services Advisory Committee (MSAC)	Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib
2007	Haute Autorite de sante (HAS)	Testing for FV Leiden and FII 20210G>A mutations
2007	Haute Autorite de sante (HAS)	Testing for Heparin-Induced thrombocytopenia
2012	Medical Services Advisory Committee (MSAC)	Testing for HER-2 status in advanced or metastatic breast cancer (stage IIIA-IV) to access lapatinib
2006	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Testing for HER2 positive breast cancer: a cost-effectiveness analysis
2007	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice
2012	Medical Services Advisory Committee (MSAC)	Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab
2012	Medical Services Advisory Committee (MSAC)	Testing for HER2 status in gastric cancer for access to trastuzumab
2003	ECRI	Testing for HER2/NEU status in breast cancer
2017	Adelaide Health Technology Assessment (AHTA)	Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2015	Adelaide Health Technology Assessment (AHTA)	Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2023	Ontario Health	Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2013	Medical Services Advisory Committee (MSAC)	Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies
2013	Agency for Healthcare Research and Quality (AHRQ)	Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment
2021	NIHR Health Technology Assessment programme	Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2020	National Institute for Health and Care Excellence (NICE)	Testing strategies for Lynch syndrome in people with endometrial cancer. NICE diagnostics guidance 42
2003	Finnish Office for Health Care Technology Assessment (Finohta)	Testing the regional application of information technology (IT) in social welfare and health care (Satakunta Macropilot project)
2005	NIHR Health Technology Assessment programme	Testing treatments on animals: relevance to humans
2014	Health Quality Ontario (HQO)	Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review
2013	HAYES, Inc.	Testosterone for low sexual desire in nonsurgically postmenopausal women
2009	HAYES, Inc.	Testosterone for low sexual desire in premenopausal women
2009	HAYES, Inc.	Testosterone for low sexual desire in surgically postmenopausal women
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Testosterone reference ranges for gender diverse individuals
2002	The Swedish Council on Health Technology Assessment (SBU)	Testosterone replacement in men with age-related hormone deficiency - early assessment briefs (ALERT)
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Tests for early diagnosis of sepsis
2022	Norwegian Institute of Public Health (NIPH)	Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2017	National Institute for Health and Care Excellence (NICE)	Tests in secondary care to identify people at high risk of ovarian cancer. NICE diagnostics guidance 31
2020	National Institute for Health and Care Excellence (NICE)	Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test). NICE diagnostics guidance 39
2003	Health Council of the Netherlands Gezondheidsraad (GR)	Tetanus prophylaxis in injuries
2006	Health Council of the Netherlands Gezondheidsraad (GR)	Tetrachloroethane; Health-based recommended occupational exposure limit
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Texture analysis of Radiological images (TexRAD) for lung cancer assessment
2021	Institute for Clinical and Economic Review (ICER)	Tezepelumab for severe asthma
2023	National Institute for Health and Care Excellence (NICE)	Tezepelumab for treating severe asthma. NICE technology appraisal guidance 880
2014	NIHR Horizon Scanning Centre (NIHR HSC)	TH-302 in combination with doxorubicin for locally advanced or metastatic, unresectable soft tissue sarcoma – first line
1999	ECRI	Thalamic stimulation for Parkinson's disease
1996	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Thalamic stimulation for tremor treatment (systematic review, primary research, expert panel)
2000	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Thalamus stimulation for the treatment of pharmacotherapy resistant tremor - primary research
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy
2002	NIHR Horizon Scanning Centre (NIHR HSC)	Thalidomide for multiple myeloma - horizon scanning review
2004	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Thalidomide for the treatment of multiple myeloma
2010	Health Council of the Netherlands Gezondheidsraad (GR)	The 'thousand-dollar genome': an ethical exploration
1999	Health Council of the Netherlands Gezondheidsraad (GR)	The 1998 reports of the Health Council of the Netherlands (Executive summaries)
2020	European Network for Health Technology Assessment (EUnetHTA)	The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment and assessment of cardiovascular disease risk
2014	NIHR Health Technology Assessment programme	The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for acute severe asthma
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	The ABCD2 scoring system for transient ischemic attacks: a review of the diagnostic accuracy and predictive value
2004	Centre for Clinical Effectiveness (CCE)	The accuracy of bioelectric impedance analysis in assessing fat free mass in patients with chronic obstructive pulmonary disease
2008	Institute of Health Economics (IHE)	The Actim™ Partus versus the TLIIQ® System as rapid response tests to aid in diagnosing preterm labour in symptomatic women
2021	NIHR Health Technology Assessment programme	The ACUTE (Ambulance CPAP: Use, Treatment effect and Economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
2017	NIHR Health Technology Assessment programme	The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up
2005	NIHR Health Technology Assessment programme	The analysis of critical incidents and adverse events in medicine - methodological research
2013	Agency for Healthcare Research and Quality (AHRQ)	The ankle brachial index for peripheral artery disease screening and cardiovascular disease prediction in asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force
2016	NIHR Health Technology Assessment programme	The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years
2014	Health Quality Ontario (HQO)	The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis
2014	Health Quality Ontario (HQO)	The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis
2014	Health Quality Ontario (HQO)	The appropriate use of neuroimaging in the diagnostic work-up of dementia: OHTAC recommendation
2021	NIHR Health Technology Assessment programme	The Arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix: the STOPPIT 2 RCT
2001	TNO	The artificial heart, a realistic alternative? Simulation model for dynamics of waiting lists
2017	NIHR Health Technology Assessment programme	The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
2009	Health Services Assessment Collaboration (HSAC)	The assessment and management of chronic pain in children and adolescents: an overview of selected literature.
1999	Alberta Heritage Foundation for Medical Research (AHFMR)	The assessment of telemedicine: general principles and a systematic review
1999	Finnish Office for Health Care Technology Assessment (Finohta)	The assessment of telemedicine. General principles and a systematic review
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	The association between obesity, aboriginal or indigenous people, indian or alaskan natives living in North America and residence in remote locations and severe outcomes with seasonal and pandemic influenza: a review of the clinical evidence
2020	NIHR Health Technology Assessment programme	The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study
2017	NIHR Health Technology Assessment programme	The Asymptomatic Carotid Surgery Trial-2 (ACST-2): an ongoing randomised controlled trial comparing carotid endarterectomy with carotid artery stenting to prevent stroke
2002	Agency for Healthcare Research and Quality (AHRQ)	The autopsy as an outcome and performance measure